% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Meattini:302849,
      author       = {I. Meattini and M. C. Aznar and L. Boldrini and K. Borgmann
                      and C. H. Clark and C. Faivre-Finn and E. Forde and U. A.
                      van der Heide and B. A. Jereczek-Fossa and N. Jornet and A.
                      M. Kirby and P. Ost and I. Ratosa and K. Tanderup and E.
                      Troost$^*$ and A. J. Cortese and M. Guckenberger},
      title        = {{R}epositioning {R}adiation {O}ncology at the centre of
                      integrated oncology care: {A} manifesto of the {E}uropean
                      {S}ociety for {R}adiotherapy and {O}ncology ({ESTRO}).},
      journal      = {Radiotherapy and oncology},
      volume       = {210},
      issn         = {0167-8140},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2025-01389},
      pages        = {111035},
      year         = {2025},
      abstract     = {Modern oncology increasingly relies on integrated,
                      multimodality care, yet radiation oncology remains
                      undervalued in strategic frameworks despite its central
                      therapeutic role. This ESTRO manifesto calls for a
                      repositioning of radiation oncology as a core discipline in
                      cancer care, scientifically, clinically, and politically.
                      The field now extends beyond beam delivery to encompass
                      systemic therapy integration, personalised strategies based
                      on biology and imaging, and active participation in clinical
                      decision-making and guideline development. Radiation
                      oncology contributes to treatment sequencing, synergistic
                      combinations, and innovation in areas such as radioligand
                      therapy and artificial intelligence. ESTRO's initiatives,
                      including education, research networks, and oncopolicy
                      engagement, underscore the discipline's broad scope and
                      societal value. Strategic partnerships with Pharma and
                      MedTech, alongside a renewed emphasis on equitable access,
                      are essential to sustaining progress. ESTRO invites all
                      stakeholders to recognise radiation oncology as fundamental
                      to the design, delivery, and evolution of modern cancer
                      therapy.},
      subtyp        = {Editorial},
      keywords     = {Health equity (Other) / Health policy (Other) / Multimodal
                      treatment (Other) / Oncology (Other) / Oncopolicy (Other) /
                      Radiotherapy (Other)},
      cin          = {DD01},
      ddc          = {610},
      cid          = {I:(DE-He78)DD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40659192},
      doi          = {10.1016/j.radonc.2025.111035},
      url          = {https://inrepo02.dkfz.de/record/302849},
}